Skip to main content

Advertisement

Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

BMC Medical Genomics volume 10, Article number: 11 (2017) Cite this article

Abstract

Background

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating idiopathic disease characterized by unexplained fatigue that fails to resolve with sufficient rest. Diagnosis is based on a list of symptoms and exclusion of other fatigue-related health conditions. Despite a heterogeneous patient population, immune and hypothalamic-pituitary-adrenal (HPA) axis function differences, such as enhanced negative feedback to glucocorticoids, are recurring findings in ME/CFS studies. Epigenetic modifications, such as CpG methylation, are known to regulate long-term phenotypic differences and previous work by our group found DNA methylome differences in ME/CFS, however the relationship between DNA methylome modifications, clinical and functional characteristics associated with ME/CFS has not been examined.

Methods

We examined the DNA methylome in peripheral blood mononuclear cells (PBMCs) of a larger cohort of female ME/CFS patients using the Illumina HumanMethylation450 BeadChip Array. In parallel to the DNA methylome analysis, we investigated in vitro glucocorticoid sensitivity differences by stimulating PBMCs with phytohaemagglutinin and suppressed growth with dexamethasone. We explored DNA methylation differences using bisulfite pyrosequencing and statistical permutation. Linear regression was implemented to discover epigenomic regions associated with self-reported quality of life and network analysis of gene ontology terms to biologically contextualize results.

Results

We detected 12,608 differentially methylated sites between ME/CFS patients and healthy controls predominantly localized to cellular metabolism genes, some of which were also related to self-reported quality of life health scores. Among ME/CFS patients, glucocorticoid sensitivity was associated with differential methylation at 13 loci.

Conclusions

Our results indicate DNA methylation modifications in cellular metabolism in ME/CFS despite a heterogeneous patient population, implicating these processes in immune and HPA axis dysfunction in ME/CFS. Modifications to epigenetic loci associated with differences in glucocorticoid sensitivity may be important as biomarkers for future clinical testing. Overall, these findings align with recent ME/CFS work that point towards impairment in cellular energy production in this patient population.

Open Peer Review reports

Background

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is an idiopathic disease characterized by profound and debilitating fatigue, cognitive impairment, unrefreshing sleep, autonomic manifestations and post-exertional malaise [1]. Other known diseases or health conditions that could explain the persistent presence of fatigue, such as major depression, anorexia, and bulimia nervosa are excluded prior to ME/CFS diagnosis. Resulting heterogeneity in the clinical features of ME/CFS is an obstacle to determine its biological basis.

Many studies examining the pathophysiology of ME/CFS have reported alterations in the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is a major component of the neuroendocrine system that regulates homeostatic processes, circadian rhythms, and environmental stress responses through a hormone cascade leading to the release of glucocorticoids (GCs). GCs interact with the GC receptor (GR) to regulate stress response and inflammation. ME/CFS patients show mild hypocortisolism and enhanced negative feedback response to GCs [2–4], suggesting a major role of the HPA axis in this disease.

In addition to modified HPA axis function, alterations in immune phenotype have been widely documented in ME/CFS. Although the specific patterns of differences remain unresolved, ME/CFS is associated with abnormal cytokine profiles [5, 6], lymphocyte proportions [7–9] and impaired immune functioning, notably decreased cytotoxicity [10–12]. Increased inflammation in the gut microbiome has also been associated with ME/CFS. These include reduced gut microbiome diversity, shifts towards pro-inflammatory bacterial species, and a proliferation of markers of pro-inflammatory processes in the serum [13].

Epigenetic modifications, including the methylation of DNA at CpG dinucleotides, can influence phenotypic changes in a long-term manner in response to external stimuli. DNA methylation modifications in genes involved in the HPA axis and the immune systems have been strongly linked to environmental stress conditions [14, 15]. We previously documented DNA methylome abnormalities in peripheral blood mononuclear cells (PBMCs) from sudden-onset ME/CFS patients, which were validated with bisulfite pyrosequencing [16]; these abnormalities were significantly concentrated in genes linked to immune regulation. Key questions remain as whether these epigenetic modifications impact immune cell function and their relationship to clinical features of ME/CFS.

In the present study, we mapped loci that were epigenetically modified in PBMCs and examined their sensitivity to glucocorticoids. Our goals were to determine how epigenetic patterns relate to HPA axis signaling in immune cells in ME/CFS patients, and to identify neuroimmune pathways impacted by ME/CFS.

Methods

Subject selection criteria

A pool of 231 ME/CFS diagnosed and healthy volunteers at 4 clinical sites in the USA was recruited by the SolveCFS Biobank. ME/CFS was diagnosed based on the Fukuda and Canadian criteria [1, 17]. Each volunteer answered surveys about symptoms, medication use, and medical history and completed the RAND-36 self-reported survey [18] to assess health-related quality of life. ME/CFS appears to be up to 1.5 times more likely to affect females [19]. We therefore specifically selected females for this study. From the volunteer pool, 49 ME/CFS patients and 25 healthy controls met the following criteria: 1) tested negative for HIV, AIDS, and/or Hepatitis C and 2) were white non-obese females (BMI < 30) with no prior history of immunomodulatory and/or epigenetic-active medication consumption. The latter criterion was aimed at minimizing potential confounding effects on the DNA methylome and immune response.

PBMC isolation and storage

Whole blood from each volunteer was collected in sodium heparin tubes and shipped overnight at ambient temperature room temperature to the Rutgers University’s Cell and DNA Repository where they were processed. Briefly, Peripheral Blood Mononuclear Cells (PBMCs) were isolated by Ficoll gradient centrifugation and resuspended in 1X Dulbecco’s phosphate-buffered saline (DPBS) + 1% fetal bovine serum (FBS). Cell count estimates were obtained using a ViCell XR Viability Analyzer. After counting, approximately 10×106 PBMCs were pelletized through centrifugation, dried and stored at -80 °C. The remaining PBMCs were cryopreserved in 10% dimethyl sulfoxide (DMSO), 50% FBS, and 40% Roswell Park Memorial Institute 1640 medium (RPMI-1640), distributed in 1 ml aliquots, and stored in liquid nitrogen. PBMC cell pellets and cryopreserved PBMCs were shipped on dry ice to the University of Toronto for subsequent analyses.

Genomic DNA extraction and purification

To obtain purified genomic DNA from the 49 ME/CFS patients and 25 healthy controls, we used the Omega E.Z.N.A. Tissue DNA kit following manufacturer’s instructions (Omega Bio-Tek, cat. no. D3396) on a sample of approximately 2.50×106 PBMCs from dry pellets by fractioning. DNA was eluted in Tris-EDTA buffer (10 mM Tris-CL, pH 8.5, 1 mM EDTA). We quantified its purity and concentration using a NanoDrop 2000c Spectrophotometer (Thermo Scientific, Waltham, MA, USA). Elutions were further purified using the Qiagen MinElute Reaction Cleanup Kit (Qiagen Canada, cat. no. 28204) when DNA purity did not meet standard absorbance criteria, i.e., A260/A280 = 1.8-2.0, and A260/A230 > 2.0. We diluted the purified DNA to a final concentration of approximately 100 ng/μl.

DNA methylome arrays

We used the Illumina Infinium HumanMethylation450 BeadChip (450 K) array (Genome Québec core facility, Montreal, QC) to obtain DNA methylome profiles from ME/CFS patients (n = 49) and healthy controls (n = 25). Approximately 1.5 μg of purified genomic DNA from each individual was bisulfite converted using the EZ DNA Methylation Kit (Zymo Research) and subsequently analyzed following standard Illumina protocols for the 450 K platform. The 450 K array interrogates the methylation levels of more than 480 000 CpG loci, which cover 99% of RefSeq Genes and 96% of CpG islands in the human genome. All the 450 K raw data from this project have been deposited in the Gene Expression Omnibus (GEO) database of the US National Center for Biotechnology Information NCBI under the accession number GSE93266.

DNA methylome data normalization and statistical analyses

DNA methylome profile analysis was performed in R using the Illumina Methylation Analyzer (IMA) package [20] and Minfi [21]. Data from each 450 K array were annotated according to the Human Genome Build 37 available at the UCSC Genome Browser (http://genome.ucsc.edu/). Raw probe florescence intensities were normalized by Subset-quantile Within Array Normalization (SWAN) [22]. Methylation-level values for each CpG site were estimated as beta-values. A beta value is defined as the ratio of methylated probe fluorescence intensity over total intensity (methylated plus unmethylated probe intensities). Beta-values range from 0 to 1 and are equivalent to the percentage of methylation of the CpG site [23]. DNA methylation differences on the 450 K array are known to either be confounded due to genetic polymorphisms or masked due to the large presence of invariably methylated sites in the genome [24, 25]. To optimize the number of significant DNA methylation calls, we discarded loci that met the following criteria: 1) the fluorescence intensity signal of the probe in the array was statistically indistinguishable from background (detection p-value ≤ 0.01); 2) contained SNPs, according to dbSNP versions 132, 135, and 137, either at the interrogated CpG locus or at the flanking single nucleotide extension; 3) were invariable across samples with respect to methylation (i.e., mean beta-value ≥ 0.95 or ≤ 0.05). To account for epigenetic variation that may arise from confounding factors, we corrected the beta-values for batch effects using the ComBat algorithm [26], and included age, Body Mass Index (BMI), and estimated cell compositions as covariates [27]. Differentially methylated sites were identified using the Wilcoxon-rank sum test. Benjamini-Hochberg procedure/false discovery rate (FDR) was used to correct for multiple testing. We considered loci as differentially methylated, when comparing ME/CFS patients with healthy controls, if they met the all of the following criteria: 1) mean beta-difference of ≥ 0.05; 2) nominal Wilcoxon-rank sum test p-value ≤ 0.05; and 3) FDR-corrected p-value of ≤ 0.05. In addition, we performed a Pearson Chi-Squared Test in R to compare differences in proportion of differential methylation according to genic region and distance from a known CpG island. To further evaluate the significance of association between methylation beta-values in each locus and dexamethasone suppression assay subgroups, we performed non-parametric permutation tests in R. To do so, we generated null distributions of the mean beta-difference per locus by: 1) Randomly reordering the dexamethasone suppression assay subgroup assignments in each comparison (i.e., control vs. ME/CFS GC-Hypersensitive, control vs. ME/CFS GC-Typical, ME/CFS GC-Hypersensitive vs. ME/CFS GC-Typical); 2) Calculating the mean beta-difference per probe; and 3) Repeating steps 1 and 2 10,000 times. Approximate p-values for each randomization test were calculated as the proportion of mean beta-difference values in the generated null distribution that were equal or more extreme than the observed value for each probe.

To identify potential functions and cellular locations of genes associated with differentially methylated loci, we performed a Gene Ontology (GO) analysis using the program DAVID [28, 29]. Enrichment Map [30] was used to cluster GO terms according to the amount of gene overlap and were textually summarized using the WordCloud plugin.

DNA methylation validation by bisulfite pyrosequencing

We used a nested primer design to enhance amplification of regions targeted for methylation analysis by bisulfite pyrosequencing. First, ‘nested’ bisulfite pyrosequencing assays for the loci of interest were designed using the Qiagen PyroMark Assay Design Software 2.0. Additional ‘outside’ primers targeting regions that encapsulated those targeted by the PyroMark assay designs were designed using Primer3 [31, 32]. Genomic DNA (300 ng) was bisulfite converted using the Zymo EZ DNA Methylation-Gold Kit according to the manufacturer’s instructions. After bisulfite conversion, 15 ng of bisulfite converted DNA was subjected to PCR to obtain biotinylated products for pyrosequencing. Each sample was amplified with 200 μM of dNTPs, 200 nM of forward and reverse primer (listed in Table 3), and 0.625 units of NEB Thermopol Taq Polymerase. The thermocycling protocol for the outside PCR was: 1 cycle of 95 °C/30 s; 30 cycles of 95 °C/30 s, 57 °C/30 s, and 68 °C/30 s; and 1 cycle of 68 °C/5 min. The thermocycling protocol for the nested PCR was: 1 cycle of 95 °C/30 s; 30 cycles of 95 °C/30 s, 53 °C/30 s, and 68 °C/30 s; and 1 cycle of 68 °C/5 min. Bisulfite pyrosequencing was performed on a Pyromark Q106 ID pyrosequencer with Pyromark Q-CpG 1.0.9 software.

Dexamethasone suppression assay and association with DNA methylation differences

Cryopreserved PBMCs were available from ME/CFS patients (n = 33) and healthy controls (n = 24) that were also examined by DNA methylome array (see above). These cells were gently thawed in a 37 °C water bath for 5–7 min and were counted using a hemocytometer (Thermo Fisher) and assessed for viability by Trypan blue exclusion. After thawing, all samples had > 95% viability. Based on our preliminary experiments, 4.0×105 live PBMCs were cultured for 4 days at 37 °C, 5% CO2 in RPMI-1640 + 10% fetal bovine serum [33] according to the following treatments: 1) A control treatment with cells and culture media only; 2) A stimulated treatment where cells were cultured with 5 μg/ml phytohaemagglutinin (PHA); and 3) a suppressed condition where cells were cultured with 5 μg/ml PHA and 10-6 M dexamethasone. Bromodeoxyuridine (BrdU) was added into each well on the 3rd day of culture and cell proliferation was assessed using the Roche BrdU colorimetric ELISA kit. The percentage of inhibition was then calculated using the average values of each experimental condition with the following formula:

$$ \mathrm{Inhibition}\%=\frac{\mathrm{Stimulated}-\mathrm{Suppressed}}{\mathrm{Stimulated}}\times 100\% $$

All assays were performed in triplicate.

We used a two-tailed t-test test to identify between-group differences in dexamethasone response, including subgroups of ME/CFS patient based on preliminary observations of a binomial distribution in the patient data. We also performed logistic regression and Pearson correlations in R to explore if ME/CFS onset type or RAND-36 scores were associated with differences in GC sensitivity. Significant differentially methylated sites in subgroups that differed in their dexamethasone suppression response were assessed according to the following statistical criteria: 1) Mean beta-difference of ≥ 0.05; and 2) nominal Wilcoxon-rank sum test p-value ≤ 0.05.

Association between clinical data and DNA methylation

Significant differentially methylated CpG sites shared between comparisons were examined to determine sites that were potentially related to glucocorticoid (GC) sensitivity and ME/CFS. To detect significant associations between health-related quality of life RAND-36 scores and DNA methylome data, we performed principal component analyses (PCA), linear regression, and FDR-correction using the stats package in R. We restricted this analysis to differentially methylated regions, defined according to the 450 K annotations and having a minimum of 2 sites with mean beta-difference ≥ 0.05, to reduce statistical noise. Two-tailed t-tests were performed on demographic information and RAND-36 scores, and a one-tailed t-test was performed on pyrosequencing data were compared using IBM SPSS Software (Version 22).

Results

RAND-36 scores are significantly lower in ME/CFS patients

Overall, ME/CFS patients had lower health-related quality of life than healthy controls, scoring significantly lower in 7 of the 8 RAND-36 categories (all p-values ≤ 0.05; Table 1). There were no differences in the average age or BMI of the clinical groups. Principal component analysis (PCA) was performed on the RAND-36 scores in order to reduce the dimensionality of the variation in scores across all categories to have a more interpretable measure of how overall score on the RAND-36 can distinguish between ME/CFS and controls. PCA showed clear a separation between ME/CFS patients and controls, with the first two principal components (PCs) explaining 85.1% of the total variation in the data (Additional file 1: Figure S1).

Table 1 Demographic data of ME/CFS and healthy control patients
Full size table

DNA methylome differences in ME/CFS

We observed 12,608 significant differentially methylated loci in our cohort after correcting for age, BMI, and differences in cell proportions (Additional file 2: Table S1). For 5,544 of these loci, the probe was annotated to a known protein coding gene according to the UCSC Genome Browser, indicating they were associated with genes. The top 5 hypo- and hypermethylated sites according to the magnitude of methylation differences are listed in Table 2. In terms of the direction of methylation differences in ME/CFS patients compared to healthy controls, 71.6% of the differentially methylated loci were hypermethylated and 28.4% were hypomethylated (Additional file 3: Figure S2A). We categorized probes according to their annotated genic locations and their distance from a known CpG island in order to determine if differential methylation was enriched at particular regions in the genome. While there were no significant differences in proportion of hypo-/hypermethylated sites according to genic location (Additional file 3: Figure S2B), there were significant differences in these proportions when considering distance from a CpG island (Additional file 3: Figure S2C). The amount of hypermethylation decreased as distance increased from a CpG island (p < 0.05, Additional file 3: Figure S2C). Specifically, probes found in the N Shore (up to 2 kb upstream of a CpG island), both N and S Shelf regions (2–4 kb from a CpG island), and the Open Sea (outside of Shelf regions) significantly differed in proportion of hypo-/hypermethylation when compared to CpG islands (all FDR < 0.05, Additional file 3: Figure S2C). S Shelf probes also exhibited decreased hypermethylation compared to neighboring S Shore probes (FDR < 0.05, Additional file 3: Figure S2C).

Table 2 Top hypo- and hypermethylated sites between ME/CFS and healthy controls
Full size table

Glucocorticoid sensitivity in PBMCs in ME/CFS subgroups

Overall, there was a significant mean increase in glucocorticoid sensitivity in PBMCs from ME/CFS patients compared to healthy controls (p ≤ 0.05). A visual inspection of the data revealed a bimodal distribution of glucocorticoid sensitivity within the ME/CFS cohort: a GC-Hypersensitive group (circled in red in Fig. 1), who exhibited an increased response to glucocorticoid treatment compared to the mean control (p ≤ 0.05) response, and a GC-Typical group (p ≤ 0.05; circled in blue in Fig. 1), who exhibited a response similar to the healthy controls in our clinical cohort. Differences in GC sensitivity were not associated with type of ME/CFS onset or the RAND-36 survey when considering scores on the overall survey or in particular categories (p > 0.10, all comparisons).

Fig. 1
figure1

Dexamethasone suppression assay results. Dexamethasone suppression results from PBMCs of ME/CFS patients (n = 33) and healthy controls (n = 24) after stimulation with PHA. Inhibition % represents the amount of suppressed cell replication with 10-6 M dexamethasone compared to stimulated and unstimulated conditions. Each point represents the mean % inhibition of a single subject. The mean is represented along with standard error bars. Glucocorticoid sensitivity was greater among ME/CFS patients overall compared to healthy controls and between ME/CFS GC-Hypersensitive (red circle) compared to ME/CFS GC-Typical (blue circle; p’s ≤0.05)

Full size image

DNA methylation differences in dexamethasone assay subgroups via pyrosequencing and permutation tests

To determine the association between differences in DNA methylation and glucocorticoid sensitivity, we applied the same statistical criteria used to identify methylation differences between ME/CFS patients and healthy controls (see Methods) to 3 different comparisons: 1) ME/CFS GC-Hypersensitive vs. ME/CFS GC-Typical; 2) ME/CFS GC-Hypersensitive vs. Controls; and 3) ME/CFS GC-Typical vs. Controls. We found that no methylation differences met these statistical criteria. However, a large number of loci exhibited significant nominal Wilcoxon-rank sum test p-values ≤ 0.05. As alternative methods of examining statistical confidence in the 3 glucocorticoid sensitivity comparisons, we evaluated the differences found with the 450 K array via targeted bisulfite pyrosequencing and genome-wide permutation of the data.

For pyrosequencing analysis, our strategy was to select 3 loci that showed nominally significant differences between ME/CFS GC-Hypersensitive and ME/CFS GC-Typical: 2 loci in JRK and 1 locus in SLC6A4. These sites were chosen to examine the reliability of the 450 K array to detect significant differences both above and below the 5% cutoff that we implemented to search for significant differentially methylated sites in ME/CFS and to specifically validate DNA methylation differences that are both potentially related to GC sensitivity differences as well as unique to ME/CFS (see Methods). The JRK sites were selected for the following reasons: these were among the top sites in terms of magnitude difference that showed a >5% methylation difference on the 450 K array, where cg24634471 showed a 21.4% difference (nominal p = 0.017) and cg10596483 20.8% difference (nominal p = 0.014) between ME/CFS GC-Hypersensitive and ME/CFS GC-Typical, and these sites were also close together in the genome (5 bp apart), which allowed us to infer how the DNA methylation status of a probe is reflected in probes within the same annotated genic region. The SLC6A4 site (cg20592995) was among the top sites showing <5% difference based on magnitude difference, and showed a 3% methylation difference (nominal p = 0.038) on the 450 K array between ME/CFS GC-Hypersensitive and ME/CFS GC-Typical. After pyrosequencing (primers listed in Table 3), the JRK sites were declared to be significant (p ≤0.05; Fig. 2a and b) or trending (p ≤0.10; Fig. 2B) according to pyrosequencing results. However, the <5% nominally significant difference found in the 450 K array data for SLC6A4 was not significant in the bisulfite pyrosequencing assay (Fig. 2c), indicating that methylation differences <5% on the 450 K array were not reliably detected for these comparison conditions.

Table 3 Bisulfite pyrosequencing primers
Full size table
Fig. 2
figure2

Bisulfite pyrosequencing of nominally significant sites. Pyrosequencing (white) results of (a) cg24634471, (b) cg10596483, and (c) cg20592995, sites that showed nominal significance on the 450 K array (black) when comparing means of ME/CFS GC-Hypersensitive (n = 14), ME/CFS GC-Typical (n = 19), and healthy controls (n = 33) assessed using an in vitro dexamethasone suppression assay. Error bars represent standard error. Lines indicate the group comparisons, where the first symbol indicates the result when compared using the 450 K array while the second statistic indicates the result compared by pyrosequencing. * = p ≤0.05, # = p ≤0.10, t-test

Full size image

For permutation analysis, we examined the amount of overlap between the sites with a >5% mean methylation difference that were nominally significant on the 450 K array according to the Wilcoxon rank-sum test and the sites that were declared to be significantly different using 10,000 permutations. We found that a majority of the nominally significant probes were also significant according to the permutation test: 76.8% in the ME/CFS GC-Hypersensitive vs. ME/CFS GC-Typical comparison, 84.5% in the ME/CFS GC-Hypersensitive vs. Control comparison, and 99.6% in the ME/CFS GC-Typical vs. Control comparison, indicating that the majority of methylation differences that were nominally significant with >5% mean methylation difference likely reflected differential methylation.

Given these results, we implemented the 5% difference cutoff across the various dexamethasone assay subgroup comparisons, and examined sites that were found to be significant using both the Wilcoxon rank-sum test and the permutation test. To determine potential epigenomic loci associated with glucocorticoid sensitivity, we examined the overlap in nominally significant loci across the three comparisons (Additional file 4: Table S2; Fig. 3). There were 5 sites that were differentially methylated across all 3 comparisons (Additional file 4: Table S2); one of which corresponded to a coding gene: NPAS3, a gene implicated in neurogenesis. We found 13 loci that were differentially methylated in both the ME/CFS GC-Hypersensitive vs. Controls (green) and ME/CFS GC-Hypersensitive vs. ME/CFS GC-Typical (blue) comparisons (Fig. 3). These loci, listed in Table 4 (full annotation information in Additional file 5: Table S3) with corresponding permutation results (Additional file 6: Figure S3), are likely associated with glucocorticoid sensitivity. The top 3 sites that showed the greatest magnitude of differences when comparing ME/CFS GC-Hypersensitive to GC-Typical subjects (ME/CFS and Controls) were corresponded to GSTM1 (14.3% increase in methylation), MYO3B (13.7% increase), and GSTM5 (12.0% increase; Fig. 4). In addition to these glucocorticoid sensitive sites, we found 4,699 loci likely associated with ME/CFS, as they were differentially methylated in the ME/CFS GC-Hypersensitive vs. Control (blue) and ME/CFS GC-Typical vs. Control (red) comparisons (Fig. 3, Additional file 7: Table S4). GO analysis of these sites revealed an enrichment of differential methylation in ME/CFS associated with regulatory processes, including neuronal cell development, signal transduction, metabolic regulation, and transcription regulation (Fig. 5, Additional file 7: Table S4). There were 203 significant differentially methylated sites that were unique to ME/CFS GC-Typical subjects (Fig. 3, Additional file 8: Table S5), however no GO terms were significantly associated with these sites.

Fig. 3
figure3

Venn diagram comparing the number of differentially methylated sites across three comparisons. Venn diagram depicting the overlap between the ME/CFS GC-Hypersensitive vs. ME/CFS GC-Typical (green), ME/CFS GC-Hypersensitive vs. Control (blue), and ME/CFS GC-Typical vs. Control (red) comparisons. Numbers within each circle and overlap correspond to the number of differentially methylated CpG sites

Full size image
Table 4 Epigenetic loci associated with GC sensitivity in ME/CFS
Full size table
Fig. 4
figure4

Top 3 glucocorticoid sensitive sites, based on magnitude of methylation difference. Increased methylation was observed at GpG sites of (a) GSTM1, (b) MYO3B, and (c) GSTM5 in the ME/CFS GC-Hypersensitive (black) compared to ME/CFS GC-Typical (grey) and Controls (white). * = p ≤0.05, Wilcoxon rank-sum test

Full size image
Fig. 5
figure5

Enriched biological themes in differentially methylated sites that are likely associated with ME/CFS. A network map of 4,699 CpG sites showing significantly different methylation associated with ME/CFS, grouped according to GO terms and summary annotations (boxes). The size of the nodes (red circles) is proportional to the number of genes within each GO term and the thickness of the edges (green lines) represents the number of genes in common between GO terms

Full size image

Relationships between differentially methylated regions and health-related quality of life

To examine the association of DNA methylation with health-related quality of life, we used the first principal component (PC1), explaining 68.4% of the variance in RAND-36 scores (Additional file 1: Figure S1B), in our linear regression analysis. We examined gene regions for this analysis in order to to determine potential epigenomic regions that show a significant relationship with quality of life scores. After linear regression analysis, we found over 1,600 differentially methylated regions with a >5% methylation difference between CFS and controls that showed a significant relationship with overall RAND-36 score (Additional file 9: Table S6). The top 5 differentially methylated regions based on R2 are shown in Table 5, and corresponded to TSS methylation in GRAMD1A, ATP6V0E2, LOC144571, and gene body methylation in LOC401431 and IL6R.

Table 5 Epigenomic regions associated with quality of life
Full size table

Discussion

In this study, we detected 12,608 differentially methylated sites in PBMCs of ME/CFS patients compared to healthy controls, some of which were significantly associated with self-reported quality of life health scores. 71.6% of these sites were hypermethylated in ME/CFS and hypermethylation was found to decrease as distance from a CpG island increased, suggesting that epigenetic dysregulation in ME/CFS significantly varies depending on relative location to CpG islands. Within the ME/CFS patient group, we observed two distinct subgroups based on in vitro sensitivity to glucocorticoid exposure. The difference in glucocorticoid sensitivity was associated with differential methylation in 13 sites on the basis of comparisons between differential methylation in both ME/CFS GC-Hypersensitive compared to ME/CFS GC-Typical and ME/CFS GC-Hypersensitive compared to healthy controls.

DNA methylation modifications in cellular processes/metabolism pathways in ME/CFS

Genes associated with cellular and metabolic regulation were major pathways showing differential epigenetic profiles in ME/CFS compared to healthy controls. These findings are consistent with a previous report by our group in sudden onset ME/CFS patients [16] and with other reports of genomic, transcriptomic, and metabolomic differences in ME/CFS [34–37], which may indicate a role for DNA methylation modifications in the metabolic stress observed in this disease. Oxidative and nitrosative stress states have been documented in immune cells from ME/CFS patients [38, 39] and a reduction in electron transport chain metabolites [37] suggests a role for processes affecting mitochondrial function in ME/CFS pathology. There is a known relationship between oxidative stress and epigenetic modifications. DNA lesions are often produced from oxidative stress states, which in turn affect the multiple levels of epigenetic regulation, leading to aberrant DNA methylation and gene expression patterns [40]. It is possible that oxidative stress, as indicated by the differences found in cellular and metabolic regulation genes in our study including ARL4C and HOXA11 (Additional file 2: Table S1; also see [41]), may drive some of the epigenetic changes observed in ME/CFS. However, additional work is required to explore this relationship, such as characterizing the effect of ARL4C and HOXA11 on DNA methylation patterns with functional genomics experiments.

Genes associated with neuronal cell development were also a major class of genes differentially methylated in ME/CFS patients. At least two previous studies that examined gene expression patterns in PBMCs of ME/CFS patients also reported significant differences genes involving neuronal development and regulatory processes [42, 43]. It is also known that genes associated with psycho-neuroendocrine-immune pathways show rich expression profiles in PBMCs [44, 45]. DNA methylation differences in neuronal genes in PBMCs could reflect some central differences in psycho-neuroendocrine-immune pathways in ME/CFS, as suggested by our glucocorticoid sensitivity assay results, which aligns with previous work identifying peripheral blood and immune cells as suitable candidates reflective of DNA methylation differences in central systems [46–48].

Dexamethasone response subgroups in ME/CFS

We observed a mean increase in glucocorticoid sensitivity in ME/CFS patients, which could not be explained based on type of ME/CFS onset or quality of life. In addition, a finer examination of our results revealed two subgroups among ME/CFS patients. Mild hypocortisolism and enhanced negative feedback to glucocorticoids were observed in several studies of GC responses in ME/CFS [3, 49]. The presence of both the GC-Typical and GC-Hypersensitive subgroups within our ME/CFS cohort thus aligns with the observed heterogeneity of HPA-related differences in these previous reports.

Glucocorticoids are known for their anti-inflammatory effects and are typically used to suppress immune responses. However, inappropriate response to glucocorticoid treatment is associated with increased susceptibility to metabolic and cardiac diseases [50]. Our results using PHA, a T cell mitogen, as an immune stressor indicate a functional impairment in T cell GR sensitivity in ME/CFS GC-Hypersensitive patients. Additional evidence suggests that T cells are candidates for a primary immune cell population in ME/CFS pathology. For example, a recent GWAS found significant differences in polymorphisms associated with T cell receptors in ME/CFS patients [51]. In addition, DNA methylation differences have been reported in CD4+ T cells from ME/CFS patients [52], a cell population that appears to show and increased dexamethasone sensitivity in ME/CFS [53].

We found 13 sites associated with glucocorticoid sensitivity in ME/CFS GC-Hypersensitive patients compared to both GC-typical ME/CFS patients and healthy controls. To our knowledge, no other EWAS or GWAS studies have specifically examined epigenetic or genetic differences in the context of GC sensitivity. However, genomic studies of ME/CFS have reported polymorphisms in GC signaling genes in ME/CFS patients. Interestingly, these genes do not appear to overlap with other disorders characterized by impaired GC signaling [51, 54]. In addition, FKBP5, a gene that was recently found to be differentially methylated in Cushing’s syndrome [55], was not among the genes identified in our study. At present, however, the potential link between ME/CFS and epigenetic modification of these genes should therefore be viewed with caution. Nevertheless, the results suggest that epigenetic differences at these sites may provide useful information regarding associated GC sensitivity among some ME/CFS patients.

Six of the 13 sites were part of known coding genes, four of which have roles in cellular metabolism. Patatin Like Phospholipase Domain Containing 4 (PNPLA4) is a phospholipase that plays a role in lipid metabolism and is highly expressed in metabolically active tissue [56]. PNPLA4 is also part of the PNPLA family, which activates upon glucocorticoid interaction [57]. D-aspartate Oxidase (DDO) is an enzyme that deaminizes D-aspartate and N-methyl D-aspartate, which is abundant in neuroendocrine tissue. Gene knockout studies of DDO in mice have revealed that this enzyme is important in melanocortin production [58] and involved in regulating basal corticosterone levels [59]. Phosphodiesterase 1C (PDE1C) is responsible for the hydrolysis of cyclic nucleotides, which is important for physiological regulation, calcium signaling pathways, and circadian rhythms [60]. Cell culture work has shown that inhibition of PDE1C via siRNA knockdown results in inhibited cell proliferation [61] and that PDE1C is activated upon dexamethasone treatment [62].

The top 3 sites, based on magnitude difference between ME/CFS GC-Hypersensitive and GC-Typical (ME/CFS and control) subjects, corresponded to GSTM1, MYO3B, and GSTM5, all of which showed >10% increase in methylation. GSTM1 and GSTM5 are part of the mu class of the GST gene family, whose primary role is the detoxification of environmental and exogenous toxins, specifically polycyclic aromatic hydrocarbons [63]. Genetic polymorphisms in GSTM are known to predict the potential response to glucocorticoid treatment in acute childhood lymphoblastic leukemia [64], indicating that GSTM may have a significant role in glucocorticoid signaling in immune cells. MYO3B is an ATPase that is activated by actin and is involved in kinase activity [65]. However, MYO3B and its various interactions remain poorly characterized compared to other myosin genes, making it unclear how differences in MYO3B may relate to glucocorticoid signaling.

The 13 differentially methylated sites could be considered to be biomarkers of glucocorticoid hypersensitivity, however additional work is required to understand and confirm the functional impact of hypermethylation on these genes and its relationship to glucocorticoid signaling. Gene knockout and RNA knockdown studies can assist in determining the precise impact that these genes have on glucocorticoid signaling. Measuring mRNA transcripts, methylation differences, and protein levels of these genes at baseline, PHA-stimulated, and DEX-suppressed conditions both in vitro and in vivo would provide a better understanding of the dynamics underlying GC sensitivity differences in ME/CFS.

DNA methylation modifications associated with quality of life health scores

We found over 1600 differentially methylated regions that were significantly associated with overall RAND-36 score (Table 5; Additional file 10: Table S7), where variation in methylation at these particular regions was significantly associated with variation in the overall RAND-36 score. Scores from this survey may point towards alterations in biological systems. Notably, of the top 5 differentially methylated regions (Table 5), ATP6V0E2 (R 2 = 0.226) is an isoform of the H(+)-ATPase V0 e subunit, which is important for cellular energy [66], LOC401431 (R 2 = 0.224) encodes the antisense RNA for ATP6V0E2 suggesting that the regulation dynamics of this particular gene may be affected in ME/CFS, IL6R (R 2 = 0.220) encodes for the receptor of IL-6, a pleiotropic cytokine, and LOC144571 (R 2 = 0.220) is the antisense RNA to alpha-2-macroglobulin, a protease inhibitor and cytokine transporter. The low Physical Health scores in ME/CFS patients (Table 1) suggest that the physical impairment in ME/CFS is associated with an epigenetic imbalance of cellular energy, metabolism, and immune signaling.

Conclusions

Here, we report DNA methylation differences in PBMCs of ME/CFS patients, some of which were significantly associated with overall quality of life as well as glucocorticoid hypersensitivity in a subgroup of ME/CFS patients. Notably, we determined epigenetic loci associated with differences in glucocorticoid sensitivity (Table 4) that may reflect underlying ME/CFS pathology in some patients. Additional work is required to confirm the potential mechanistic relationships between DNA methylation in these genes of interest, downstream gene expression and protein profiles, and ME/CFS phenotype. Longitudinal studies both in vivo and in vitro are needed to assess the stability of these epigenetic modifications, including changes in symptom profiles and in response to glucocorticoid treatment. For example, cytokines such as IL-10 and IFN-gamma, which were differentially methylated in our study (Additional file 7: Table S4), are known to interact with GR and show expression differences in vitro upon dexamethasone treatment [53, 67]. While GR density and binding affinity in ME/CFS PBMCs do not appear to differ in steady state conditions [4], GR is known to be upregulated during exercise challenge in ME/CFS [68]. Future work should examine DNA methylation signatures during exercise challenge in ME/CFS in order to gain a better understanding of glucocorticoid signaling dynamics. Nevertheless, at the very least, the differentially methylated sites identified in this study may be important as biomarkers for future clinical testing in order to determine if epigenetic changes in these genes associate with disease onset or progression.

The results of this study highlight the potential utility of immune cell subtyping within the ME/CFS population, and indicate that epigenetic data may aid in elucidating relevant biological pathways impacted by ME/CFS. Clinical investigations of the regulation of cellular metabolism are needed to assess this possibility, as we found that genes such as GSTM1, MYO3B, GSTM5, and ATP6V0E2 showed significant epigenetic modifications in ME/CFS. Increased understanding of ME/CFS subtypes will assist patients and physicians to determine the appropriate interventions to treat symptoms and improve personal health.

Abbreviations

450 K:

Illumina infinium humanMethylation450 beadChip

BMI:

Body mass index

BrdU:

Bromodeoxyuridine

DMSO:

Dimethyl sulfoxide

DPBS:

Dulbecco’s phosphate-buffered saline

ELISA:

Enzyme-linked immunosorbent assay

FBS:

Fetal bovine serum

FDR:

Benjamini-Hochberg procedure/false discovery rate

GC:

Glucocorticoid

GEO:

Gene expression omnibus

GO:

Gene ontology

GR:

Glucocorticoid receptor

GST:

Glutathione-S-transferase

HPA:

Hypothalamic-pituitary-adrenal

IMA:

Illumina methylation analyzer

ME/CFS:

Myalgic encephalomyelitis/chronic fatigue syndrome

PBMCs:

Peripheral blood mononuclear cells

PCA:

Principal component analysis

PCR:

Polymerase chain reaction

RAND-36:

The RAND 36-item health survey

RPMI-1640:

Roswell park memorial institute 1640 medium

SNP:

Single nucleotide polymorphism

SWAN:

Subset-quantile within array normalization

TSS:

Transcription start site

UTR:

Untranslated region

References

  1. 1.

    Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med. 1994;121(12):953–9.

  2. 2.

    Gaab J, Huster D, Peisen R, Engert V, Schad T, Schurmeyer TH, Ehlert U. Low-dose dexamethasone suppression test in chronic fatigue syndrome and health. Psychosom Med. 2002;64(2):311–8.

  3. 3.

    Van Den Eede F, Moorkens G, Van Houdenhove B, Cosyns P, Claes SJ. Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. Neuropsychobiology. 2007;55(2):112–20.

  4. 4.

    Visser J, Lentjes E, Haspels I, Graffelman W, Blauw B, de Kloet R, Nagelkerken L. Increased sensitivity to glucocorticoids in peripheral blood mononuclear cells of chronic fatigue syndrome patients, without evidence for altered density or affinity of glucocorticoid receptors. J Investig Med. 2001;49(2):195–204.

  5. 5.

    Landi A, Broadhurst D, Vernon SD, Tyrrell DL, Houghton M. Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome. Cytokine. 2016;78:27–36.

  6. 6.

    Rajeevan MS, Dimulescu I, Murray J, Falkenberg VR, Unger ER. Pathway-focused genetic evaluation of immune and inflammation related genes with chronic fatigue syndrome. Hum Immunol. 2015;76(8):553–60.

  7. 7.

    Brenu EW, Huth TK, Hardcastle SL, Fuller K, Kaur M, Johnston S, Ramos SB, Staines DR, Marshall-Gradisnik SM. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol. 2014;26(4):233–42.

  8. 8.

    Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, Klimas NG, Marshall-Gradisnik SM. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011;9:81.

  9. 9.

    Curriu M, Carrillo J, Massanella M, Rigau J, Alegre J, Puig J, Garcia-Quintana AM, Castro-Marrero J, Negredo E, Clotet B, et al. Screening NK-B- and T-cell phenotype and function in patients suffering from chronic fatigue syndrome. J Transl Med. 2013;11:68.

  10. 10.

    Bradley AS, Ford B, Bansal AS. Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Exp Immunol. 2013;172(1):73–80.

  11. 11.

    Fluge O, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Naess H, Dahl O, Nyland H, Mella O. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One. 2011;6(10):e26358.

  12. 12.

    Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28(6):1403–10.

  13. 13.

    Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4(1):30.

  14. 14.

    Garden GA. Epigenetics and the modulation of neuroinflammation. Neurotherapeutics. 2013;10(4):782–8.

  15. 15.

    Sasaki A, de Vega WC, McGowan PO. Biological embedding in mental health: an epigenomic perspective. Biochem Cell Biol. 2013;91(1):14–21.

  16. 16.

    de Vega WC, Vernon SD, McGowan PO. DNA methylation modifications associated with chronic fatigue syndrome. PLoS One. 2014;9(8):e104757.

  17. 17.

    Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327–38.

  18. 18.

    Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33(5):350–7.

  19. 19.

    Reyes M, Nisenbaum R, Hoaglin DC, Unger ER, Emmons C, Randall B, Stewart JA, Abbey S, Jones JF, Gantz N, et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med. 2003;163(13):1530–6.

  20. 20.

    Wang D, Yan L, Hu Q, Sucheston LE, Higgins MJ, Ambrosone CB, Johnson CS, Smiraglia DJ, Liu S. IMA: an R package for high-throughput analysis of Illumina’s 450 K infinium methylation data. Bioinformatics (Oxford, England). 2012;28(5):729–30.

  21. 21.

    Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, Irizarry RA. Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. Bioinformatics (Oxford, England). 2014;30(10):1363–9.

  22. 22.

    Maksimovic J, Gordon L, Oshlack A. SWAN: subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. Genome Biol. 2012;13(6):R44.

  23. 23.

    Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, Esteller M. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011;6(6):692–702.

  24. 24.

    Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, Gallinger S, Hudson TJ, Weksberg R. Discovery of cross-reactive probes and polymorphic CpGs in the illumina infinium HumanMethylation450 microarray. Epigenetics. 2013;8(2):203–9.

  25. 25.

    Lam LL, Emberly E, Fraser HB, Neumann SM, Chen E, Miller GE, Kobor MS. Factors underlying variable DNA methylation in a human community cohort. Proc Natl Acad Sci U S A. 2012;109 Suppl 2:17253–60.

  26. 26.

    Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical bayes methods. Biostatistics (Oxford, England). 2007;8(1):118–27.

  27. 27.

    Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinf. 2012;13:86.

  28. 28.

    da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.

  29. 29.

    da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.

  30. 30.

    Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5(11):e13984.

  31. 31.

    Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics (Oxford, England). 2007;23(10):1289–91.

  32. 32.

    Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. Primer3--new capabilities and interfaces. Nucleic Acids Res. 2012;40(15):e115.

  33. 33.

    Creed TJ, Lee RW, Newcomb PV, di Mambro AJ, Raju M, Dayan CM. The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J Immunol. 2009;183(1):164–71.

  34. 34.

    Carmel L, Efroni S, White PD, Aslakson E, Vollmer-Conna U, Rajeevan MS. Gene expression profile of empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics. 2006;7(3):375–86.

  35. 35.

    Presson AP, Sobel EM, Papp JC, Suarez CJ, Whistler T, Rajeevan MS, Vernon SD, Horvath S. Integrated weighted gene co-expression network analysis with an application to chronic fatigue syndrome. BMC Syst Biol. 2008;2:95.

  36. 36.

    Whistler T, Taylor R, Craddock RC, Broderick G, Klimas N, Unger ER. Gene expression correlates of unexplained fatigue. Pharmacogenomics. 2006;7(3):395–405.

  37. 37.

    Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, Gordon E. Metabolic features of chronic fatigue syndrome. Proceedings of the National Academy of Sciences. 2016;113(37):E5472–E5480.

  38. 38.

    Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry. 2009;22(1):75–83.

  39. 39.

    Morris G, Berk M, Klein H, Walder K, Galecki P, Maes M. Nitrosative stress, hypernitrosylation, and autoimmune responses to nitrosylated proteins: new pathways in neuroprogressive disorders including depression and chronic fatigue syndrome. Molecular neurobiology. 2016;1:1–21.

  40. 40.

    Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008;266(1):6–11.

  41. 41.

    Fernández-Ayala DJ, Guerra I, Jiménez-Gancedo S, Cascajo MV, Gavilán A, DiMauro S, Hirano M, Briones P, Artuch R, De Cabo R, Salviati L. Survival transcriptome in the coenzyme Q10 deficiency syndrome is acquired by epigenetic modifications: a modelling study for human coenzyme Q10 deficiencies. BMJ open. 2013;3(3):e002524.

  42. 42.

    Kaushik N, Fear D, Richards SC, McDermott CR, Nuwaysir EF, Kellam P, Harrison TJ, Wilkinson RJ, Tyrrell DA, Holgate ST, et al. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol. 2005;58(8):826–32.

  43. 43.

    Vernon SD, Unger ER, Dimulescu IM, Rajeevan M, Reeves WC. Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers. 2002;18(4):193–9.

  44. 44.

    Nicholson AC, Unger ER, Mangalathu R, Ojaniemi H, Vernon SD. Exploration of neuroendocrine and immune gene expression in peripheral blood mononuclear cells. Brain Res Mol Brain Res. 2004;129(1-2):193–7.

  45. 45.

    Vernon SD, Nicholson A, Rajeevan M, Dimulescu I, Cameron B, Whistler T, Lloyd A. Correlation of psycho-neuroendocrine-immune (PNI) gene expression with symptoms of acute infectious mononucleosis. Brain Res. 2006;1068(1):1–6.

  46. 46.

    Horvath S, Zhang Y, Langfelder P, Kahn RS, Boks MP, van Eijk K, van den Berg LH, Ophoff RA. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 2012;13(10):R97.

  47. 47.

    Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics. 2013;8(10):1030–8.

  48. 48.

    Provencal N, Suderman MJ, Guillemin C, Massart R, Ruggiero A, Wang D, Bennett AJ, Pierre PJ, Friedman DP, Cote SM, et al. The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells. J Neurosci. 2012;32(44):15626–42.

  49. 49.

    Papadopoulos AS, Cleare AJ. Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol. 2012;8(1):22–32.

  50. 50.

    Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.

  51. 51.

    Schlauch KA, Khaiboullina SF, De Meirleir KL, Rawat S, Petereit J, Rizvanov AA, Blatt N, Mijatovic T, Kulick D, Palotas A, et al. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome. Transl Psychiatry. 2016;6:e730.

  52. 52.

    Brenu EW, Staines DR, Marshall-Gradisbik SM. Methylation profile of CD4+ T cells in chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Cell Immunol. 2014;5:228.

  53. 53.

    Visser J, Blauw B, Hinloopen B, Brommer E, de Kloet ER, Kluft C, Nagelkerken L. CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. J Infect Dis. 1998;177(2):451–4.

  54. 54.

    Rajeevan MS, Smith AK, Dimulescu I, Unger ER, Vernon SD, Heim C, Reeves WC. Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome. Genes Brain Behav. 2007;6(2):167–76.

  55. 55.

    Resmini E, Santos A, Aulinas A, Webb SM, Vives-Gilabert Y, Cox O, Wand G, Lee RS. Reduced DNA methylation of FKBP5 in Cushing’s syndrome. Endocrine. 2016;54(3):768–77.

  56. 56.

    Watt MJ, Steinberg GR. Regulation and function of triacylglycerol lipases in cellular metabolism. Biochem J. 2008;414(3):313–25.

  57. 57.

    Jaworski K, Sarkadi-Nagy E, Duncan RE, Ahmadian M, Sul HS. Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue. Am J Physiol Gastrointest Liver Physiol. 2007;293(1):G1–4.

  58. 58.

    Huang AS, Beigneux A, Weil ZM, Kim PM, Molliver ME, Blackshaw S, Nelson RJ, Young SG, Snyder SH. D-aspartate regulates melanocortin formation and function: behavioral alterations in D-aspartate oxidase-deficient mice. J Neurosci. 2006;26(10):2814–9.

  59. 59.

    Weil ZM, Huang AS, Beigneux A, Kim PM, Molliver ME, Blackshaw S, Young SG, Nelson RJ, Snyder SH. Behavioural alterations in male mice lacking the gene for D-aspartate oxidase. Behav Brain Res. 2006;171(2):295–302.

  60. 60.

    Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis. 2015;21(1):e25–50.

  61. 61.

    Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, Yuan JX, Insel PA. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol Lung Cell Mol Physiol. 2007;292(1):L294–303.

  62. 62.

    Ahlstrom M, Pekkinen M, Huttunen M, Lamberg-Allardt C. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells. Biochem Pharmacol. 2005;69(2):267–75.

  63. 63.

    Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, Lan Q, Boffetta P, Vineis P, Autrup H, Bell DA, et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol. 2002;156(2):95–109.

  64. 64.

    Marino S, Verzegnassi F, Tamaro P, Stocco G, Bartoli F, Decorti G, Rabusin M. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer. 2009;53(6):984–91.

  65. 65.

    Dose AC, Burnside B. A class III myosin expressed in the retina is a potential candidate for bardet-biedl syndrome. Genomics. 2002;79(5):621–4.

  66. 66.

    Blake-Palmer KG, Su Y, Smith AN, Karet FE. Molecular cloning and characterization of a novel form of the human vacuolar H + -ATPase e-subunit: an essential proton pump component. Gene. 2007;393(1-2):94–100.

  67. 67.

    Visser J, Graffelman W, Blauw B, Haspels I, Lentjes E, de Kloet ER, Nagelkerken L. LPS-induced IL-10 production in whole blood cultures from chronic fatigue syndrome patients is increased but supersensitive to inhibition by dexamethasone. J Neuroimmunol. 2001;119(2):343–9.

  68. 68.

    Meyer JD, Light AR, Shukla SK, Clevidence D, Yale S, Stegner AJ, Cook DB. Post-exertion malaise in chronic fatigue syndrome: symptoms and gene expression. Fatigue. 2013;1(4):190–204.

Download references

Acknowledgements

We would like to thank Dr. Benjamin Hing for his assistance with pyrosequencing validation, and Drs. Rene Harrison, Bebhinn Treanor, Cara Fiorino, and He-song Sun for their assistance with the dexamethasone suppression assay.

Funding

This work was funded by startup funds from the University of Toronto and an operating grant from the Solve ME/CFS Initiative awarded to POM. SH was the recipient of a postdoctoral fellowship for ME/CFS research awarded by the Canadian Institutes of Health Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The dataset supporting the conclusions of this article is available in the GEO repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93266.

Authors’ contributions

POM designed research; WCDV performed research; WCDV, SH, POM analyzed the data; SDV contributed reagents/materials; WCDV, SH, SDV, POM wrote the manuscript. All authors read and approved the final manuscript.

Authors’ information

SDV is the Research Liaison of the Bateman Horne Center of Excellence.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study adhered to the human experimentation guidelines as outlined by the Helsinki Declaration of 1975. The collection of and analysis of clinical information and biological samples by the SolveCFS BioBank was ethically approved by the Genetic Alliance ethics review board (IRB # IORG0003358) and the University of Toronto (IRB #27391), which also approved all procedures for obtaining written informed consent from all participants in the study. Two copies of the consent form were signed, with one copy provided to the participants and one copy under secure storage at the SolveCFS Biobank.

Author information

Affiliations

  1. Department of Biological Sciences, University of Toronto, Scarborough, 1265 Military Trail, Toronto, ON, M1C 1A4, Canada
    • Wilfred C. de Vega
    • , Santiago Herrera
    •  & Patrick O. McGowan
  2. Department of Cell and Systems Biology, University of Toronto, Toronto, ON, Canada
    • Wilfred C. de Vega
    •  & Patrick O. McGowan
  3. Department of Psychology, University of Toronto, Toronto, ON, Canada
    • Patrick O. McGowan
  4. Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
    • Patrick O. McGowan
  5. Solve ME/CFS Initiative, Los Angeles, CA, USA
    • Suzanne D. Vernon
  6. Present affiliation: Department of Biological Sciences, Lehigh University, Bethlehem, PA, USA
    • Santiago Herrera
  7. Present affiliation: The Bateman Horne Center of Excellence, Salt Lake City, UT, USA
    • Suzanne D. Vernon
Authors
  1. Search for Wilfred C. de Vega in:
  2. Search for Santiago Herrera in:
  3. Search for Suzanne D. Vernon in:
  4. Search for Patrick O. McGowan in:

Corresponding author

Correspondence to Patrick O. McGowan.

Additional files

Additional file 1: Figure S1.

PCA results of RAND-36 scores. (A) Principal components (PCs; columns) and the amount of variance each PC accounts for in the data (B) RAND-36 principal component scores of PC1 against PC2 for ME/CFS (red) and control (green) subjects. Loadings for (C) PC1 and (D) PC2 are separated according to the 8 different categories of RAND-36. (TIF 161 kb)

Additional file 2: Table S1.

Differentially methylated sites in ME/CFS. Sites that were significantly differentially methylated between ME/CFS and controls (FDR ≤ 0.05, Beta-difference ≥ 5% ). (XLSX 1.58 mb)

Additional file 3: Figure S2.

Distribution of differential methylation in ME/CFS. The distribution and genic locations of differentially methylated loci in ME/CFS patients compared to healthy controls (n = 12,608). (A) The proportion of probes that are either hypomethylated (decreased methylation, white) or hypermethylated (increased methylation, black) in ME/CFS patients. The proportion of hypo- and hypermethylated probes according to (B) genic regions or (C) location relative to CpG islands are displayed. Line above bars = Main effect of region, * = p <0.05, Pearson Chi-Squared test. * = post-hoc FDR < 0.05, comparison with CpG island, unless indicated by hooked lines. (TIF 219 kb)

Additional file 4: Table S2.

High confidence differentially methylated sites according to Dexamethasone assay subgroups. Differentially methylated sites between the 3 different subgroups (ME/CFS GC-Hypersensitive, ME/CFS GC-Typical, and Healthy Controls) from the Dexamethasone assay (p ≤0.05, Beta-difference ≥ 5%, after 10 000 permutations). (XLSX 2.88 mb)

Additional file 5: Table S3.

Differentially methylated sites that relate to GC sensitivity in ME/CFS. Full annotation of 13 sites that relate to GC sensitivity in ME/CFS GC-Hypersensitive subjects (p ≤0.05, Beta-difference ≥ 5%, after 10 000 permutations). (XLSX 48.9 kb)

Additional file 6: Figure S3.

Permutation results of GC sensitive sites. Beta-difference distributions of the 13 sites potentially associated with GC sensitivity after 10,000 permutations, according to (A) ME/CFS GC-Hypersensitive vs. ME/CFS GC-Typical, (B) ME/CFS GC-Hypersensitive vs. Controls, and (C) ME/CFS GC-Typical vs. Controls. The red line in each panel indicates the location of the distribution where p <0.05 and the blue line indicates the observed beta-difference on the 450 K array. (TIF 3.44 mb )

Additional file 7: Table S4.

High confidence epigenetic biomarkers for ME/CFS. Epigenetic loci that relate to general ME/CFS pathology (p ≤ 0.05, Beta-difference ≥ 5%, after 10 000 permutations). (XLSX 543 kb)

Additional file 8: Table S5.

Gene ontology (GO) terms associated with differential methylation in ME/CFS. GO terms of the sites associated with ME/CFS (FDR ≤ 0.10). (XLSX 74.8 kb)

Additional file 9: Table S6.

Differentially methylated sites unique to ME/CFS GC-Typical. Epigenetic loci that are specifically differentially methylated in the ME/CFS GC-Typical subgroup (p ≤ 0.05, Beta-difference ≥ 5%, after 10 000 permutations). (XLSX 24 kb)

Additional file 10: Table S7.

Epigenomic regions that are significantly related to quality of life. Genes and associated regions that showed significant associations between RAND-36 overall quality of life and DNA methylation (FDR ≤ 0.05). (XLSX 168 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

de Vega, W.C., Herrera, S., Vernon, S.D. et al. Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). BMC Med Genomics 10, 11 (2017) doi:10.1186/s12920-017-0248-3

Download citation

Keywords

  • Chronic fatigue syndrome
  • Myalgic encephalomyelitis
  • Epigenetics
  • Dna methylation
  • Glucocorticoid
  • Hpa axis
  • Immune cells

BMC Medical Genomics

ISSN: 1755-8794

Contact us